- Home
- ETON vs EBS Comparison
ETON vs EBS Comparison
Compare ETON & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- EBS
- Stock Information
- Founded
- ETON 2017
- EBS 1998
- Country
- ETON United States
- EBS United States
- Employees
- ETON N/A
- EBS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- EBS Health Care
- Exchange
- ETON Nasdaq
- EBS Nasdaq
- Market Cap
- ETON 498.8M
- EBS 423.6M
- IPO Year
- ETON 2018
- EBS 2006
- Fundamental
- Price
- ETON $18.35
- EBS $12.45
- Analyst Decision
- ETON Strong Buy
- EBS Strong Buy
- Analyst Count
- ETON 3
- EBS 2
- Target Price
- ETON $29.67
- EBS $13.50
- AVG Volume (30 Days)
- ETON 249.9K
- EBS 1.2M
- Earning Date
- ETON 11-06-2025
- EBS 10-29-2025
- Dividend Yield
- ETON N/A
- EBS N/A
- EPS Growth
- ETON N/A
- EBS N/A
- EPS
- ETON N/A
- EBS 1.35
- Revenue
- ETON $58,181,000.00
- EBS $788,900,000.00
- Revenue This Year
- ETON $105.25
- EBS N/A
- Revenue Next Year
- ETON $40.84
- EBS $19.24
- P/E Ratio
- ETON N/A
- EBS $9.51
- Revenue Growth
- ETON 85.40
- EBS N/A
- 52 Week Low
- ETON $8.24
- EBS $4.02
- 52 Week High
- ETON $23.00
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- ETON 45.34
- EBS 73.19
- Support Level
- ETON $18.00
- EBS $9.21
- Resistance Level
- ETON $18.92
- EBS $13.41
- Average True Range (ATR)
- ETON 0.83
- EBS 0.61
- MACD
- ETON -0.12
- EBS 0.26
- Stochastic Oscillator
- ETON 45.30
- EBS 78.38
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.